Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose

INTRODUCTION: Pridopidine is a highly selective sigma-1 receptor (S1R) agonist in development for the treatment of Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS). Pridopidine’s activation of S1R enhances cellular processes that are crucial for neuronal function and survival but ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Darpo, Borje, Geva, Michal, Ferber, Georg, Goldberg, Yigal Paul, Cruz-Herranz, Andres, Mehra, Munish, Kovacs, Richard, Hayden, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043059/
https://www.ncbi.nlm.nih.gov/pubmed/36811812
http://dx.doi.org/10.1007/s40120-023-00449-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043059/
https://www.ncbi.nlm.nih.gov/pubmed/36811812
http://dx.doi.org/10.1007/s40120-023-00449-w

Ejemplares similares